Status:
COMPLETED
An Observational Study of Herceptin (Trastuzumab) in Patients With HER2-positive Advanced Gastric Cancer
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Gastric Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This observational, multicenter study will assess the efficacy and safety of Herceptin (trastuzumab) in routine clinical practice in patients with HER2-positive advanced adenocarcinoma of the stomach ...
Eligibility Criteria
Inclusion
- Adult patients, \>/=18 years of age
- Histologically confirmed advanced adenocarcinoma of the stomach or gastro-esophageal junction (GEJ) with locally advanced and/or metastatic disease
- HER2-positive tumor
- Patients who are eligible for treatment with Herceptin according to the judgment of the physician
Exclusion
- Unwilling or unable to sign informed consent form
- Any contraindications, interactions and incompatibilities to Herceptin
Key Trial Info
Start Date :
April 16 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2016
Estimated Enrollment :
443 Patients enrolled
Trial Details
Trial ID
NCT01220934
Start Date
April 16 2010
End Date
June 1 2016
Last Update
June 20 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Krankenhaus Nordwest; Klinik f. Onkologie und Hämatologie
Frankfurt, Germany, 60488